086450 — DongKook Pharmaceutical Co Income Statement
0.000.00%
- KR₩747bn
- KR₩815bn
- KR₩731bn
- 79
- 43
- 76
- 79
Annual income statement for DongKook Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 482,280 | 559,103 | 594,193 | 661,647 | 730,994 |
Cost of Revenue | |||||
Gross Profit | 290,835 | 337,410 | 350,260 | 379,826 | 410,781 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 413,696 | 474,370 | 530,974 | 588,994 | 664,120 |
Operating Profit | 68,585 | 84,733 | 63,219 | 72,654 | 66,873 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 75,629 | 80,031 | 69,754 | 68,632 | 60,838 |
Provision for Income Taxes | |||||
Net Income After Taxes | 59,050 | 57,880 | 52,916 | 54,757 | 48,871 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 56,312 | 55,925 | 50,345 | 52,896 | 47,175 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 56,312 | 55,925 | 50,345 | 52,896 | 47,175 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1,265 | 1,251 | 1,109 | 1,172 | 1,041 |
Dividends per Share |